Skip to main content

Astagraf XL FDA Approval History

FDA Approved: Yes (First approved July 19, 2013)
Brand name: Astagraf XL
Generic name: tacrolimus
Dosage form: Extended-Release Capsules
Company: Astellas Pharma US, Inc.
Treatment for: Organ Transplant, Rejection Prophylaxis

Astagraf XL (tacrolimus) is a calcineurin-inhibitor immunosuppressant for the prophylaxis of organ rejection in patients receiving a kidney transplant.

Development timeline for Astagraf XL

Jul 22, 2013Approval Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection
Dec 26, 2005NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.